MTOR and colorectal carcinoma: Regarding the biological significance of the ASCT2 inhibitor, Schulte et al. showed that the treatment with V-9302 in colorectal cancer (CRC) cell lines resulted in decreased mTOR activity, as assessed by investigating the expression of phosphor-S6 and phosphor-AKT (Ser473), which is consistent with diminished amino acid transportation and metabolism15.